Lv6
3190 积分 2023-05-22 加入
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
7小时前
求助中
Biejiajian pill inhibits progression of hepatocellular carcinoma by downregulating PDGFRβ signaling in cancer-associated fibroblasts
4天前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
4天前
已完结
IGF-Binding Protein 7 and Cadmium-Induced Hepatorenal Fibrosis
22天前
已完结
TRIM21-mediated ubiquitination of SQSTM1/p62 abolishes its Ser403 phosphorylation and enhances palmitic acid cytotoxicity
27天前
已完结
UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disorders
27天前
已完结
Global Burden of Major Chronic Liver Diseases in 2021
30天前
已完结
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
1个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
1个月前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
1个月前
已完结
皖公网安备34019202002308
